Newbury Pharma Q4 Revenue Up but EBITDA Loss Widens

Newbury Pharmaceuticals reported Q4 revenue of 13.6 million kronor, up from 5.9 million year-over-year, but EBITDA loss narrowed to -5.1 million from -5.9 million. The company remains loss-making despite revenue growth, indicating ongoing operational challenges.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works